Goldman Sachs’s Inhibrx INBX Stock Holding History

Goldman Sachs’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.3M	Hold	66,500	–	–	﹤0.01%	3676
2026 Q1	$4.47M	Hold	66,500	–	–	﹤0.01%	3812
2025 Q4	$5.25M	Buy	+66,500	New	+$4.53M	﹤0.01%	3693

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's INBX Position: Q2 2026 in Review

Goldman Sachs increased its Inhibrx (INBX) stake by 256% in Q2 2026, buying an estimated $24.4M and bringing the position to 338,176 shares worth $32M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Goldman Sachs first reported a position in INBX in Q3 2024 and has held it in 8 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Goldman Sachs held 338,176 shares of Inhibrx worth $32M as of Q2 2026.
Goldman Sachs bought 243,102 Inhibrx shares in Q2 2026, an estimated $24.4M.
Inhibrx made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2196 holding.
Goldman Sachs first reported a position in Inhibrx in Q3 2024 and has held it in 8 quarters since.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.